DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.
Sapience Therapeutics has dosed the first patient in its Phase 2 dose expansion study of ST316, a first-in-class β-catenin antagonist, for colorectal cancer.